West Pharmaceutical Services WST
West Pharmaceutical Services designs and manufactures high-precision packaging components and systems for the pharmaceutical and healthcare industry, such as stoppers, syringes, and drug delivery devices. West Pharmaceutical maintains solid financial health (net cash, DN/EBITDA -0.13) and double-digit growth (revenue +13.8%), but its valuation is demanding (PER 47.37, FCF yield 1.07%), which limits attractiveness despite business quality.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
West Pharmaceutical Services designs and manufactures high-precision packaging components and systems for the pharmaceutical and healthcare industry, such as stoppers, syringes, and drug delivery devices. West Pharmaceutical maintains solid financial health (net cash, DN/EBITDA -0.13) and double-digit growth (revenue +13.8%), but its valuation is demanding (PER 47.37, FCF yield 1.07%), which limits attractiveness despite business quality.
Score by category
| Category | Score |
|---|---|
| Financial health | 8.3 |
| Quality / Moat | 6.4 |
| Valuation | 2.2 |
| Growth | 7.3 |
| Dividend | 3.0 |
| Momentum | 7.9 |
| Risk & Context | 5.7 |
OVERALL SCORE: 5.7/10
Context and risks
No material exposure to interest rates, nor to commodities, nor to direct geopolitical tensions. The pharmaceutical packaging business is defensive and unaffected by the current macro context.
News considered in the analysis
- West Pharmaceutical Poised to See EPS Upside to Current 2027 Wall Street Estimates, Morgan Stanley Says — Upgrade de analista con visión positiva sobre el BPA 2027, pero es una opinión y no un hecho consumado.
- Veeva Unveils AI Study Builder Agent to Speed Clinical Trial Setup — Noticia de un competidor (Veeva) sin impacto directo en West Pharmaceutical.
- Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now — Listículo genérico sobre otra empresa, sin información nueva para West.
- Veeva Unveils Falcon Router to Streamline Biopharma Case Routing — Noticia de un competidor sin relevancia material para West.
- Here's Why You Should Retain IRTC Stock in Your Portfolio for Now — Listículo genérico sobre otra empresa, sin impacto.
Verdict: Hold: quality and growth justify the premium, but the current multiple leaves little margin of safety.
Main risk: The demanding valuation (PER 47.37) and low cash conversion (30.47%) could weigh on the stock if growth decelerates or rates keep rising.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →